Browse > Article
http://dx.doi.org/10.5483/BMBRep.2020.53.10.158

Emerging roles of 14-3-3γ in the brain disorder  

Cho, Eunsil (School of Biosystem and Biomedical Science, College of Health Science, Korea University)
Park, Jae-Yong (School of Biosystem and Biomedical Science, College of Health Science, Korea University)
Publication Information
BMB Reports / v.53, no.10, 2020 , pp. 500-511 More about this Journal
Abstract
14-3-3 proteins are mostly expressed in the brain and are closely involved in numerous brain functions and various brain disorders. Among the isotypes of the 14-3-3 proteins, 14-3-3γ is mainly expressed in neurons and is highly produced during brain development, which could indicate that it has a significance in neural development. Furthermore, the distinctive levels of temporally and locally regulated 14-3-3γ expression in various brain disorders suggest that it could play a substantial role in brain plasticity of the diseased states. In this review, we introduce the various brain disorders reported to be involved with 14-3-3γ, and summarize the changes of 14-3-3γ expression in each brain disease. We also discuss the potential of 14-3-3γ for treatment and the importance of research on specific 14-3-3 isotypes for an effective therapeutic approach.
Keywords
14-3-3 gamma; 14-3-3 protein; 14-3-$3{\gamma}$; Brain disorders; Glioma; Inflammatory disease; Neurodegenerative disease; Neurodevelopmental disease; YWHAG;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Moore BE and Perez VJ (1967) Specific acidic proteins of the nervous system. Physiological and Biochemical aspects of Nervous integration. A symposium, Prentice Hall, Englewood Cliffs, NJ. 343-359
2 Ichimura T, Isobe T, Okuyama T et al (1987) Brain 14-3-3 protein is an activator protein that activates tryptophan 5-monooxygenase and tyrosine 3-monooxygenase in the presence of Ca2+,calmodulindependent protein kinase II. FEBS Letts 219, 79-82   DOI
3 Jones DH, Ley S and Aitken A (1995) Isoforms of 14-3-3 protein can form homo- and heterodimers in vivo and in vitro: implications for function as adapter proteins. FEBS Lett 368, 55-58   DOI
4 Jin J, Smith FD, Stark C et al (2004) Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol 14, 1436-1450   DOI
5 Darling DL, Yingling J and Wynshaw-Boris A (2005) Role of 14-3-3 Proteins in Eukaryotic Signaling and Development. Curr Top Dev Biol 68, 281-315   DOI
6 Wang W and Shakes DC (1996) Molecular evolution of the 14-3-3 protein family. J Mol Evol 43, 384-398   DOI
7 Rosenquist M, Alsterfjord M, Larsson C and Sommarin M (2001) Data mining the arabidopsis genome reveals fifteen 14-3-3 genes. Expression is demonstrated for two out of five novel genes. Plant Physiol 127, 142-149   DOI
8 Su TT, Parry DH, Donahoe B, Chien CT, O'Farrell PH and Purdy A (2001) Cell cycle roles for two 14-3-3 proteins during drosophila development. J Cell Sci 114, 3445-3454   DOI
9 Selkoe DJ and Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8, 595-608   DOI
10 Iqbal K, Liu F, Gong CX and Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7, 656-664   DOI
11 Layfield R. Fergusson J, Aitken A, Lowe J, Landon M and Mayer RJ (1996) Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett 209, 57-60   DOI
12 Fountoulakis M, Cairns N, Lubec G (1999) Increased levels of $14-3-3{\gamma}$ and ${\varepsilon}$ proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 57, 323-335
13 Gu O, Cuevas E, Raymick J, Kanungo J and Sarkar S (2020) Downregulation of 14-3-3 proteins in Alzheimer's Disease. Mol Neurobiol 57, 32-40   DOI
14 National Institute of Neurological Disorders and Stroke (2003) Creutzfeldt-Jakob Disease Fact Sheet. NINDS. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet
15 Spero M and Lazibat I (2010) Creutzfeldt-Jakob disease: case report and review of the literature. Acta Clin Croat 49, 181-187
16 Hsich G, Kenney K, Gibbs CJ, Lee KH and Harrington MG (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335, 24-30
17 Masters SC, Pederson KJ, Zhang L, Barbieri JT and Fu H (1999) Interaction of 14-3-3 with a nonphosphorylated protein ligand, exoenzyme S of Pseudomonas aeruginosa. Biochemistry 38, 5216-5221   DOI
18 Jaehne EJ, Ramshaw H, Xu X et al (2015) In-vivo administration of clozapine affects behaviour but does not reverse dendritic spine deficits in the $14-3-3{\xi}$ KO mouse model of schizophrenia-like disorders. Pharmacol Biochem Behav 138, 1-8   DOI
19 Ikeda M, Hikita T, Taya S et al (2008) Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum Mol Genet 17, 3212-3222   DOI
20 Wachi T, Cornell B and Toyo-Oka K (2017) Complete ablation of the 14-3-3epsilon protein results in multiple defects in neuropsychiatric behaviors. Behav Brain Res 319, 31-36   DOI
21 Zhai J, Lin H, Shamim M, Schlaepfer WW and Canete-Soler R (2001) Identification of a novel interaction of 14-3-3 with p190RhoGEF. J Biol Chem 276, 41318-41324   DOI
22 Wang B, Yang H, Liu Y et al (1999) Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 38, 12499-12504   DOI
23 Aitken A, Baxter H, Dubois T et al (2002) Specificity of 14-3-3 isoform dimer interactions and phosphorylation. Biochem Soc Trans 30, 351-360   DOI
24 Aitken A (2011) Post-translational modification of 14-3-3 isoforms and regulation of cellular function. Semin Cell Dev Biol 22, 673-680   DOI
25 Truong AB, Masters SC, Yang H and Fu H (2002) Role of the 14-3-3 C-terminal loop in ligand interaction. Proteins 49, 321-325   DOI
26 Silhan J, Obsilova V, Vecer J et al (2004) 14-3-3 protein C-terminal stretch occupies ligand binding groove and is displaced by phosphopeptide binding. J Biol Chem 279, 49113-49119   DOI
27 Pennington KL, Chan TY, Torres MP and Andersen JL (2018) The Dynamic and stress-adaptive signaling hub of 14-3-3: Emerging mechanisms of regulation and contextdependent protein-protein interactions. Oncogene 37, 5587-5604   DOI
28 Boston PF, Jackson P, Kynoch PA and Thompson RJ (1982) Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J Neurochem 38, 1466-1474   DOI
29 Aghazadeh V and Papadopoulos Y (2016) The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today 21, 278-287   DOI
30 Zerr I, Bodemer M, Gefeller O et al (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43, 32-40   DOI
31 Shiga Y, Wakabayashi H, Miyazawa K, Kido H and Itoyama Y (2006) 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages. J Clin Neurosci 13, 661-665   DOI
32 Lemstra AW, van Meegen MT, Vreyling JP et al (2000) 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology 55, 514-516   DOI
33 Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF et al (2001) CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56, 1528-1533   DOI
34 Wiltfang J, Otto M, Baxter HC et al (1999) Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem 73, 2485-2490   DOI
35 Matsui Y, Satoh K, Miyazaki T et al (2011) High sensitivity of an ELISA kit for detection of the gammaisoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease. BMC Neurol 11, 120   DOI
36 Leitao MJ, Baldeiras I, Almeida MR et al (2016) Sporadic Creutzfeldt-Jakob disease diagnostic accuracy is improved by a new CSF ELISA $14-3-3{\gamma}$ assay. Neuroscience 322, 398-407   DOI
37 Kilani RT, Maksymowych WP, Aitken A et al (2007) Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 34, 1650-1657
38 Sardari K, Chavez-Munoz C, Kilani RT, Schiller T and Ghahary A (2011) Increased levels of the 14-3-3 ${\eta}$ and ${\gamma}$ proteins in the synovial fluid of dogs with unilateral cranial cruciate ligament rupture. Can J Vet Res 75, 271-277
39 Dougherty MK and Morrison DK (2004) Unlocking the code of 14-3-3. J Cell Sci 117, 1875-1884   DOI
40 Aitken A, Howell S, Jones D, Madrazo J and Patel Y (1995) 14-3-3 alpha and delta are the phosphorylated forms of Raf-activating 14-3-3 beta and zeta. J Biol Chem 270, 5706-5709   DOI
41 van Heusden GP (2005) 14-3-3 proteins: regulators of numerous eukaryotic proteins. IUBMB Life 57, 623-629   DOI
42 Bridges D and Moorhead GB (2004) 14-3-3 proteins: a number of functions for a numbered protein. Sci STKE 296, re10
43 Sluchanko NN and Gusev NB (2017) Moonlighting chaperone-like activity of the universal regulatory 14-3-3 proteins. FEBS J 284, 1279-1295   DOI
44 Fan X, Cui L, Zeng Y et al (2019) 14-3-3 proteins are on the crossroads of cancer, aging, and age-related neurodegenerative disease. Int J Mol Sci 20, 3518   DOI
45 Muslin AJ and Xing H (2000) 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal 12, 703-709   DOI
46 Obsil T and Obsilova V (2011) Structural basis of 14-3-3 protein functions. Semin Cell Dev Biol 22, 663-672   DOI
47 Fu H, Subramanian RR and Masters SC (2000) 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40, 617-647   DOI
48 Yaffe MB, Volinia S, Caron PR et al (1997) The Structural basis for 14-3-3: phosphopeptide Binding Specificity. Cell 91, 961-971   DOI
49 Chaudhri M, Scarabel M and Aitken A (2003) Mammalian and yeast 14-3-3 isoforms form distinct patterns of dimers in vivo. Biochem Biophys Res Commun 300, 679-685   DOI
50 Wilker EW, Grant RA, Artim SC and Yaffe MB (2005) 14-3-3 proteins: a family of versatile molecular regulators. J Biol Chem 280, 18891-18898   DOI
51 Leffers H, Madsen P, Rasmussen HH et al (1993) Molecular cloning and expression of the transformation sensitive epithelial marker stratifin. A member of a protein family that has been involved in the protein kinase C signalling pathway. J Mol Biol 231, 982-998   DOI
52 Watanabe M, Isobe T, Ichimura T, Kuwano R, Takahashi Y and Kondo H (1993) Molecular cloning of rat cDNAs for beta and gamma subtypes of 14-3-3 protein and developmental changes in expression of their mRNAs in the nervous system. Brain Res Mol Brain Res 17, 135-146   DOI
53 Xiong XX, Hu DX, Xu L et al (2019) Selective $14-3-3{\gamma}$ upregulation promotes Beclin-1-LC3-Autophagic Influx via ${\beta}$-catenin interaction in starved neurons in vitro and in vivo. Neurochem Res 44, 849-858   DOI
54 Gerber KJ, Squires KE and Hepler JR (2018) $14-3-3{\gamma}$ binds regulator of G protein signaling 14 (RGS14) at distinct sites to inhibit the RGS14:$G{\alpha}_{i}-AIF_{4}^{-}$ signaling complex and RGS14 nuclear localization. J Biol Chem 293, 14616-14631   DOI
55 Civiero L, Cogo S, Kiekens A et al (2017) PAK6 Phosphorylates $14-3-3{\gamma}$ to Regulate Steady State Phosphorylation of LRRK2. Front Mol Neurosci 10, 417   DOI
56 Lee YS, Lee JK, Bae Y et al (2016) Suppression of $14-3-3{\gamma}$-mediated surface expression of ANO1 inhibits cancer progression of glioblastoma cells. Sci Rep 6, 26413   DOI
57 Constantinescu CS, Farooqi N, O'Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164, 1079-1106   DOI
58 Lee D, Steinacker P, Seubert S et al (2015) Role of glial 14-3-3 gamma protein in autoimmune demyelination. J Neuroinflammation 6, 187
59 Dendrou CA, Fugger L and Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15, 545-558   DOI
60 Nakahara J, Maeda M, Aiso S and Suzuki N (2012) Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol 42, 26-34   DOI
61 Pirim I (1998) Ischemic rat brains contain immunoreactivity of 14-3-3 proteins. Int J Neurosci 95, 101-106   DOI
62 Kawamoto Y, Akiguchi I, Tomimoto H, Shirakashi Y, Honjo Y and Budka H (2006) Upregulated expression of 14-3-3 proteins in astrocytes from human cerebrovascular ischemic lesions. Stroke 37, 830-835   DOI
63 Fujii K, Tanabe Y, Kobayashi K, Uchikawa H and Kohno Y (2005) Detection of 14-3-3 protein in the cerebrospinal fluid in mitochondrial encephalopathy with lactic acidosis and stroke-like episodes. J Neurol Sci 239, 115-118   DOI
64 Lai XJ, Ye SQ, Zheng L et al (2014) Selective $14-3-3{\gamma}$ induction quenches p-${\beta}$-catenin Ser37/Bax-enhanced cell death in cerebral cortical neurons during ischemia. Cell Death Dis 5, e1184   DOI
65 Wachi T, Cornell B, Marshall C, Zhukarev V, Baas PW and Toyo-oka K (2016) Ablation of the 14-3-3gamma protein results in neuronal migration delay and morphological defects in the developing cerebral cortex. Dev Neurobiol 76, 600-614   DOI
66 Oh SJ, Woo J, Lee YS et al (2016) Direct interaction with $14-3-3{\gamma}$ promotes surface expression of Best1 channel in astrocyte. Mol Brain 10, 51
67 Cho CH, Kim E, Lee YS et al (2014) Depletion of $14-3-3{\gamma}$ reduces the surface expression of Transient Receptor Potential Melastatin 4b (TRPM4b) channels and attenuates TRPM4b-mediated glutamate-induced neuronal cell death. Mol Brain 7, 52   DOI
68 Jang SW, Liu X, Fu H et al (2009) Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. J Biol Chem 284, 24512-24525   DOI
69 Zhou XY, Hu DX, Chen RQ et al (2017) 14-3-3 Isoforms differentially regulate $NF{\kappa}B$ signaling in the brain after ischemia-reperfusion. Neurochem Res 42, 2354-2362   DOI
70 Cornell B and Toyo-Oka K (2017) 14-3-3 proteins in brain development: neurogenesis, neuronal migration and neuromorphogenesis. Front Mol Neurosci 10, 318   DOI
71 JC Yoo, N Park, B Lee et al (2017) $14-3-3{\gamma}$ regulates Copine1-mediated neuronal differentiation in HiB5 hippocampal progenitor cells. Exp Cell Res 356, 85-92   DOI
72 Cornell B, Wachi T, Zhukarev V and Toyo-Oka K (2016) Overexpression of the $14-3-3{\gamma}$ protein in embryonic mice results in neuronal migration delay in the developing cerebral cortex. Neurosci Lett 628, 40-46   DOI
73 Hillier L, Fulton R, Fulton L et al (2003) The DNA sequence of chromosome 7. Nature 424, 157-164   DOI
74 Morris CM, Mervis CB, Paciorkowski AP et al (2015) Osborne 7q11.23 duplication syndrome: physical characteristics and natural history. Am J Med Genet A 167A, 2916-2935
75 Ramocki MB, Bartnik M, Szafranski P et al (2010) Recurrent distal 7q11.23 deletion including HIP1 and YWHAG identified in patients with intellectual disabilities, epilepsy, and neurobehavioral problems. Am J Hum Genet 87, 857-865   DOI
76 Fusco C, Micale L, Augello B et al (2014) Smaller and larger deletions of the Williams Beuren syndrome region implicate genes involved in mild facial phenotype, epilepsy and autistic traits. Eur J Hum Genet 22, 64-70   DOI
77 Nicita F, Garone G, Spalice A et al (2016) Epilepsy is a possible feature in Williams-Beuren syndrome patients harboring typical deletions of the 7q11.23 critical region. Am J Med Genet A 170A, 148-155
78 Chen XQ and Yu AC (2002) The association of 14-3-3gamma and actin plays a role in cell division and apoptosis in astrocytes. Biochem Biophys Res Commun 296, 657-663   DOI
79 Otsuka S, Sakakima H, Terashi T, Takada S, Nakanishi K and Kikuchi K (2019) Preconditioning exercise reduces brain damage and neuronal apoptosis through enhanced endogenous $14-3-3{\gamma}$ after focal brain ischemia in rats. Brain Struct Funct 224, 739-740   DOI
80 Dong Y, Liu HD, Zhao R et al (2009) Ischemia activates JNK/c-Jun/AP-1 pathway to up-regulate 14-3-3gamma in astrocyte. J Neurochem 109, 182-188   DOI
81 Chen XQ, Chen JG, Zhang Y, Hsiao WW and Yu AC (2003) 14-3-3gamma is upregulated by in vitro ischemia and binds to protein kinase Raf in primary cultures of astrocytes. Glia 42, 315-324   DOI
82 Umahara T, Uchihara T, Tsuchiya K et al (2007) Intranuclear localization and isoform-dependent translocation of 14-3-3 proteins in human brain with infarction. J Neurol Sci 260, 159-166   DOI
83 Chen XQ, Fung YW and Yu AC (2005) Association of 14-3-3gamma and phosphorylated bad attenuates injury in ischemic astrocytes. J Cereb Blood Flow Metab 25, 338-347   DOI
84 Dong Y, Liu HD, Zhao R et al (2009) Ischemia activates JNK/c-Jun/AP-1 pathway to up-regulate 14-3-3gamma in astrocyte. J Neurochem 109, 182-188   DOI
85 Pang Y, Chai CR, Gao K et al (2015) Ischemia preconditioning protects astrocytes from ischemic injury through $14-3-3{\gamma}$. J Neurosci Res 93, 1507-1518   DOI
86 Bull MJ (2020) Down syndrome. N Engl J Med 382, 2344-2352   DOI
87 Schindler CK, Heverin M and Henshall DC (2016) Isoform- and subcellular fraction-specific differences in hippocampal 14-3-3 levels following experimentally evoked seizures and in human temporal lobe epilepsy. J Neurochem 99, 561-569   DOI
88 Smani D, Sarkar S, Raymick J, Kanungo J, Paule MG and Gu Q (2018) Downregulation of 14-3-3 proteins in a kainic acid-induced neurotoxicity model. Mol Neurobiol 55, 122-129   DOI
89 Guella I, McKenzie MB, Evans DM et al (2017) De Novo mutations in YWHAG cause early-onset epilepsy. Am J Hum Genet 101, 300-310   DOI
90 Fountoulakis M, Cairns N and Lubec G (1999) Increased levels of $14-3-3{\gamma}$ and ${\varepsilon}$ proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 57, 323-335
91 Chen H, Burton EA, Webster RG et al (2013) Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications. Environ. Health Perspect 121, 11-12
92 Hermeking H and Benzinger A (2006) 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 16, 183-192   DOI
93 Morrison DK (2009) The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19, 16-23   DOI
94 Gardino AK, Smerdon SJ and Yaffe MB (2006) Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol 16, 173-182   DOI
95 Yang X, Lee WH, Sobott F et al (2006) Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci U S A 103, 17237-17242   DOI
96 Tzivion G, Luo Z and Avruch J (1998) A Dimeric 14-3-3 protein is an essential cofactor for Raf Kinase Activity. Nature 394, 88-92   DOI
97 Peyril A, Weitzdoerfer R, Gulesserian T, Fountoulakis M and Lubec G (2002) Aberrant expression of signalingrelated proteins $14-3-3{\gamma}$ and RACK1 in fetal Down syndrome brain (trisomy 21). Electrophoresis 23, 152-157   DOI
98 Hughes AJ, Ben-Shlomo Y, Daniel SE and Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42, 1142-1146   DOI
99 Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson's disease. J Neurochemistry 139, 318-324   DOI
100 Jellinger KA (2009) Formation and development of Lewy pathology: a critical update. J Neurology 256, 270-279   DOI
101 Goedert M, Spillantini MG, Del Tredici K and Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9, 13-24   DOI
102 Rittinger K, Budman J, Xu J et al (1999) Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell 4, 153-166   DOI
103 Zhou Y, Reddy S, Murrey H, Fei H and Levitan IB (2003) Monomeric 14-3-3 protein is sufficient to modulate the activity of the drosophila slowpoke calcium-dependent potassium channel. J Biol Chem 278, 10073-10080   DOI
104 Xiao B, Smerdon SJ, Jones DH et al (1995) Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways. Nature 376, 188-191   DOI
105 Liu D, Bienkowska J, Petosa C, Collier RJ, Fu H and Liddington R (1995) Crystal structure of the zeta isoform of the 14-3-3 protein. Nature 376, 191-194   DOI
106 Coblitz B, Shikano S, Wu M et al (2005) C-terminal recognition by 14-3-3 proteins for surface expression of membrane receptors. J Biol Chem 280, 36263-36272   DOI
107 Coblitz B, Wu M, Shikano S and Li M (2006) C-terminal binding: an expanded repertoire and function of 14-3-3 proteins. FEBS Lett 580, 1531-1535   DOI
108 Petosa C, Masters SC, Bankston LA et al (1998) 14-3-3zeta binds a phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. J Biol Chem 273, 16305-16310   DOI
109 Ostrerova N, Petrucelli L, Farrer M et al (1999) alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19, 5782-5791   DOI
110 Wong YC and Krainc D (2017) ${\alpha}$-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23, 1-13   DOI
111 Kawamoto Y, Akiguchi I, Nakamura S, Honjyo Y, Shibasaki H and Budka H (2002) 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J Neuropathol Exp Neurol 61, 245-253   DOI
112 Cao WD, Zhang X, Zhang JN et al (2006) Immunocytochemical detection of 14-3-3 in primary nervous system tumors. J Neurooncol 77, 125-130   DOI
113 Gardino AK and Yaffe MB (2011) 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol 22, 688-695   DOI
114 Jin Y, Dai MS, Lu SZ et al (2006) 14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J 25, 1207-1218   DOI
115 Lee JH and Lu H (2011) 14-3-3gamma inhibition of MDMX-mediated p21 turnover independent of p53. J Biol Chem 286, 5136-5142   DOI
116 Cao L, Cao W, Zhang W et al (2008) Identification of 14-3-3 protein isoforms in human astrocytoma by immunohistochemistry. Neurosci Lett 432, 94-99   DOI
117 Yang X, Cao W, Lin H et al (2009) Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci 276, 54-59   DOI
118 Liang S, Xu Y, Shen G et al (2009) Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis 30, 4152-4162   DOI
119 Yacoubian TA, Slone SR, Harrington AJ et al (2010) Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Death Dis 1, e2   DOI
120 Berg D, Riess O and Bornemann A (2003) Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol 53, 135
121 Ding H, Underwood R, Lavalley N and Yacoubian TA (2015) 14-3-3 inhibition promotes dopaminergic neuron loss and $14-3-3{\theta}$ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease. Neuroscience 307, 73-82   DOI
122 Xu Z, Graham K, Foote M et al (2013) 14-3-3 protein targets misfolded chaperone-associated proteins to aggresomes. J Cell Sci 126, 4173-4186   DOI
123 Jia B, Wu Y and Zhou Y (2014) 14-3-3 and aggresome formation: implications in neurodegenerative diseases. Prion 8, 173-177   DOI
124 Plotegher N, Kumar D, Tessari I et al (2014) The chaperone-like protein $14-3-3{\eta}$ interacts with human ${\alpha}$-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing ${\alpha}$-synuclein cellular toxicity. Hum Mol Genet 23, 5615-5629   DOI
125 Sato S, Chiba T, Sakata E et al (2006) 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J 25, 211-221   DOI
126 Scheltens P, Blennow K, Breteler MM et al (2016) Alzheimer's disease. Lancet 388, 505-517   DOI
127 Com E, Clavreul A, Lagarrigue M, Michalak S, Menei P and Pineau C (2012) Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J Proteomics 75, 3898-3913   DOI
128 Cao W, Yang X, Zhou J et al (2010) Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis 15, 230-241   DOI
129 Liu J, Liu Y, Ren Y, Kang L and Zhang L (2014) Transmembrane protein with unknown function 16A overexpression promotes glioma formation through the nuclear factor-kappaB signaling pathway. Mol Med Rep 9, 1068-1074   DOI
130 Wang J, Lou H, Pedersen CJ, Smith AD and Perez RG (2009) 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 284, 14011-14019   DOI
131 Cheah PS, Ramshaw HS, Thomas PQ et al (2012) Neurodevelopmental and neuropsychiatric behavior defects arise from 14-3-3zeta deficiency. Mol Psychiatry 17, 451-466   DOI
132 Yao ZQ, Zhang X, Zhen Y et al (2018) A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma. Cell Death Dis 9, 767   DOI
133 Steinacker P, Schwarz P, Reim K et al (2005) Unchanged Survival Rates of $14-3-3{\gamma}$ Knockout Mice after Inoculation with Pathological Prion Protein. Mol Cell Biol 25, 1339-1346   DOI
134 Kim DE, Cho CH, Sim KM et al (2019) $14-3-3{\gamma}$ haploinsufficient mice display hyperactive and stress-sensitive behaviors. Exp Neurobiol 28, 43-45   DOI
135 Xu X, Jaehne EJ, Greenberg Z et al (2015) 14-3-3zeta deficient mice in the BALB/c background display behavioral and anatomical defects associated with neurodevelopmental disorders. Sci Rep 5, 12434   DOI